NVLS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Nivalis Therapeutics Inc's research and development for the six months ended in Mar. 2015 was $11.37 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2015 was $12.20 Mil.
This is the expense the company spent on research and development.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nivalis Therapeutics Inc Research & Development for the trailing twelve months (TTM) ended in Mar. 2015 was $12.20 Mil.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Nivalis Therapeutics Inc Annual Data
|Research & Development||0.00||0.00||0.00||0.00||0.00||0.00||0.00||7.10||13.14||12.20|
Nivalis Therapeutics Inc Semi-Annual Data
|Research & Development||0.00||0.00||0.00||0.00||0.00||0.00||7.10||13.14||12.20||11.37|